Truist analyst Asthika Goonewardene raised the firm’s price target on Gilead (GILD) to $145 from $127 and keeps a Buy rating on the shares. The company’s Q3 results supports the view of a stable base business, but while HIV remains the primary driver with improving PrEP execution, oncology results were mixed and cell therapy continues to face competitive pressure despite broader site access, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GILD:
- Gilead Sciences’ Earnings Call Highlights Growth and Optimism
- Gilead Sciences: Strong Performance and Future Potential Drive Buy Rating
- Gilead price target raised to $147 from $143 at Morgan Stanley
- Gilead price target raised to $105 from $100 at RBC Capital
- Hookipa Pharma completes sale of HBV, HIV assets to Gilead